Peter Kaiser Sells 2,810 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Peter Kaiser sold 2,810 shares of Ocular Therapeutix stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $8.28, for a total transaction of $23,266.80. Following the sale, the insider owned 269,108 shares in the company, valued at approximately $2,228,214.24. This represents a 1.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL traded up $0.55 during mid-day trading on Wednesday, reaching $9.50. 7,845,017 shares of the company traded hands, compared to its average volume of 7,060,435. Ocular Therapeutix, Inc. has a fifty-two week low of $5.78 and a fifty-two week high of $16.44. The firm has a market cap of $2.07 billion, a PE ratio of -6.60 and a beta of 0.90. The stock has a fifty day simple moving average of $10.53 and a 200-day simple moving average of $11.62. The company has a debt-to-equity ratio of 0.11, a current ratio of 15.39 and a quick ratio of 15.32.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The business had revenue of $13.25 million during the quarter, compared to analysts’ expectations of $16.13 million. During the same quarter last year, the business posted ($0.29) earnings per share. The company’s quarterly revenue was down 22.4% on a year-over-year basis. Equities research analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Citigroup reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Chardan Capital reiterated a “buy” rating and issued a $21.00 target price on shares of Ocular Therapeutix in a research note on Wednesday, February 18th. Royal Bank Of Canada restated an “outperform” rating and set a $30.00 price target on shares of Ocular Therapeutix in a research note on Thursday, February 5th. Needham & Company LLC reduced their price objective on shares of Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, January 22nd. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $23.78.

Institutional Investors Weigh In On Ocular Therapeutix

Several hedge funds and other institutional investors have recently made changes to their positions in OCUL. Steward Partners Investment Advisory LLC increased its position in shares of Ocular Therapeutix by 124.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,242 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Ocular Therapeutix by 1.8% during the second quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company’s stock worth $674,000 after buying an additional 1,314 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Ocular Therapeutix by 62.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,392 shares in the last quarter. Trust Co. of Vermont increased its holdings in Ocular Therapeutix by 24.3% in the 4th quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,750 shares during the period. Finally, Profund Advisors LLC raised its stake in shares of Ocular Therapeutix by 9.9% in the 3rd quarter. Profund Advisors LLC now owns 25,178 shares of the biopharmaceutical company’s stock valued at $294,000 after buying an additional 2,272 shares in the last quarter. 59.21% of the stock is owned by institutional investors and hedge funds.

Ocular Therapeutix News Roundup

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Director Richard L. Lindstrom bought 60,229 shares at an average $7.66 (a ~32% increase in his stake) — a sizable insider purchase that signals confidence and provides direct demand support for the shares. Read More.
• Positive Sentiment: Ocular will present detailed SOL‑1 data at the 49th Macula Society meeting and host an investor webcast — a potential catalyst if data or management commentary clarifies commercial or clinical outlooks. Read More.
• Neutral Sentiment: The company will participate in March investor conferences, increasing visibility with institutional investors but not introducing new clinical data by itself. Read More.
• Neutral Sentiment: Several small institutional moves were reported (new / larger stakes by boutique managers). These are modest in dollar terms and mainly signal ongoing institutional interest rather than a major position shift. (No single large fund reported a material cut.)
• Negative Sentiment: Short interest jumped ~27.8% in February to ~14.7M shares (about 6.9% of shares outstanding) with a ~3.0 days‑to‑cover — higher shorting can amplify downside on negative news and adds volatility risk.
• Negative Sentiment: Multiple insiders sold shares in late Feb (including Pravin Dugel, Sanjay Nayak, Jeffrey Heier, Peter Kaiser and Nadia Waheed). While some sales are modest relative to holdings, the cluster of transactions can be perceived as a negative signal. Representative SEC disclosure: Read More.
• Negative Sentiment: Needham lowered its price target to $18 (from $20) — a downward adjustment from a sell‑side firm that could temper sentiment among growth/biotech investors. Read More.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.